Symptomatic, untreated, or uncontrolled central nervous system metastases.
Receipt of any local or systemic anticancer therapy or investigational anticancer agent within a protocol-defined washout period prior to study treatment.
Unresolved clinically significant toxicities from prior anticancer therapy
History of a another malignancy within 2 years prior to screening (exception adequately treated cancers).
